{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:39:28Z","timestamp":1784842768302,"version":"3.55.0"},"reference-count":98,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Although MGMT promoter methylation, gross-total resection (GTR), and adjuvant chemoradiation therapy are known to independently improve clinical outcomes for patients with glioblastoma (GBM), their combined influence remains unclear. In the present study, the authors investigated the complementary role of these factors in GBM prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The 2022 National Cancer Database was queried for individuals with histologically confirmed IDH-wildtype GBM WHO grade 4 and available MGMT promoter methylation status data. Demographic, clinical, and treatment-related variables were analyzed. Kaplan-Meier survival and multivariate Cox proportional hazards analyses were conducted, stratified by MGMT promoter methylation and chemoradiation therapy status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 27,858 patients were included in the analysis. Chemotherapy, radiation therapy, and MGMT promoter methylation status were independently associated with improved survival in the overall cohort (p &lt; 0.001). In Kaplan-Meier analysis, MGMT promoter methylation was associated with improved overall survival for individuals who received standard chemoradiation therapy (p &lt; 0.001) but not for individuals who did not receive chemoradiation therapy (p = 0.649). In the overall cohort, GTR was associated with a 40% improvement in overall survival relative to excisional biopsy (HR 0.633 [95% CI 0.52\u20130.77], p &lt; 0.001) in multivariate analysis. In patients with MGMT promoter\u2013methylated tumors, GTR was associated with a 70% (HR 0.30 [95% CI 0.12\u20130.71], p = 0.007) improvement in overall survival compared with excisional biopsy in those who did not receive chemoradiation therapy, but GTR did not significantly improve survival in those who received chemoradiation therapy (HR 0.97 [95% CI 0.54\u20131.73], p = 0.912). For patients with MGMT promoter\u2013unmethylated tumors, GTR was associated with improved overall survival for both those who received chemoradiation therapy (HR 0.48 [95% CI 0.33\u20130.70], p &lt; 0.001) and those who did not (HR 0.50 [95% CI 0.28\u20130.89], p = 0.018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In this large registry study, the authors demonstrated that maximizing the extent of resection improves overall survival, especially for individuals with MGMT unmethylated GBM or those not receiving chemoradiation therapy. However, the impact of gross-total resection requires further investigation in patients with MGMT promoter\u2013methylated GBM who receive adjuvant therapy. These findings support future studies exploring new diagnostic techniques for preoperative evaluation of MGMT methylation to aid surgical planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2025.5.focus25350","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:46:43Z","timestamp":1754034403000},"page":"E9","source":"Crossref","is-referenced-by-count":4,"title":["The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma"],"prefix":"10.3171","volume":"59","author":[{"given":"Megan","family":"Parker","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Carmichael","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antolin","family":"Serrano-Farias","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Alfonzo Horowitz","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calixto-Hope G.","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debraj","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Comair","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordina","family":"Rincon-Torroella","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"Supplement_6","key":"b1","series-title":"Neuro Oncol","first-page":"vi1","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021","volume":"26","author":"Price M","year":"2024","unstructured":"Price M, Ballard C, Benedetti J,  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26(Supplement_6):vi1-vi85."},{"issue":"23","key":"b2","series-title":"JAMA","first-page":"2535","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp R","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA,  Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535\u20132543."},{"issue":"1","key":"b3","series-title":"Neurosurgery","first-page":"190","article-title":"Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas","volume":"84","author":"Gessler F","year":"2019","unstructured":"Gessler F, Bernstock JD, Braczynski A,  Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas. Neurosurgery. 2019;84(1):190\u2013197."},{"issue":"2","key":"b4","series-title":"Neuro Oncol","first-page":"116","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera AL","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR,  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12(2):116\u2013121."},{"key":"b5","series-title":"Front Oncol","first-page":"1569","article-title":"The impact of surgery in IDH 1 wild type glioblastoma in relation with the MGMT deregulation","volume":"9","author":"Marchi F","year":"2019","unstructured":"Marchi F, Sahnane N, Cerutti R,  The impact of surgery in IDH 1 wild type glioblastoma in relation with the MGMT deregulation. Front Oncol. 2019;9:1569."},{"issue":"5","key":"b6","series-title":"Neuro Oncol","first-page":"940","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia P","year":"2023","unstructured":"Karschnia P, Young JS, Dono A,  Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol. 2023;25(5):940\u2013954."},{"issue":"11","key":"b7","series-title":"JAMA Oncol","first-page":"1460","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown TJ","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M,  Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460\u20131469."},{"issue":"12","key":"b8","series-title":"Ann Oncol","first-page":"3117","article-title":"Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy","volume":"24","author":"Kreth FW","year":"2013","unstructured":"Kreth FW, Thon N, Simon M,  Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117\u20133123."},{"issue":"1","key":"b9","series-title":"J Neurosurg","first-page":"156","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt MJ","year":"2009","unstructured":"McGirt MJ, Chaichana KL, Gathinji M,  Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156\u2013162."},{"issue":"1","key":"b10","series-title":"J Neurooncol","first-page":"207","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy M","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA,  Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207\u2013212."},{"issue":"10","key":"b11","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ,  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u2013996."},{"issue":"6","key":"b12","series-title":"J Pers Med","first-page":"999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan K","year":"2023","unstructured":"Ashkan K, Baig Mirza A, Soumpasis C,  MGMT promoter methylation: prognostication beyond treatment response. J Pers Med. 2023;13(6):999."},{"issue":"4","key":"b13","series-title":"Neurosurgery","first-page":"E323","article-title":"MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold","volume":"88","author":"Katsigiannis S","year":"2021","unstructured":"Katsigiannis S, Grau S, Krischek B,  MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold. Neurosurgery. 2021;88(4):E323\u2013E329."},{"key":"b14","series-title":"Front Oncol","first-page":"1087","article-title":"The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma","volume":"10","author":"Incekara F","year":"2020","unstructured":"Incekara F, Smits M, van der Voort SR,  The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma. Front Oncol. 2020;10:1087."},{"issue":"5","key":"b15","series-title":"Neuro Oncol","first-page":"958","article-title":"Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups","volume":"25","author":"Gerritsen JKW","year":"2023","unstructured":"Gerritsen JKW, Zwarthoed RH, Kilgallon JL,  Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups. Neuro Oncol. 2023;25(5):958\u2013972."},{"issue":"12","key":"b16","series-title":"JAMA Oncol","first-page":"1722","article-title":"Using the National Cancer Database for outcomes research: a review","volume":"3","author":"Boffa DJ","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K,  Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722\u20131728."},{"key":"b17","series-title":"ACS","article-title":"Participant user files","unstructured":"Participant user files. ACS. Accessed March 3, 2025. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/puf\/"},{"key":"b18","article-title":"Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition. Vol 6.","year":"2021","unstructured":"Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition. Vol 6. International Agency for Research on Cancer (IARC);2021. Accessed June 10, 2025. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Central-Nervous-System-Tumours-2021"},{"issue":"5","key":"b19","series-title":"J Chronic Dis","first-page":"373","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u2013383."},{"issue":"12","key":"b20","series-title":"Neuro Oncol","first-page":"2117","article-title":"The surgical management of diffuse gliomas: current state of neurosurgical management and future directions","volume":"25","author":"Young JS","year":"2023","unstructured":"Young JS, Morshed RA, Hervey-Jumper SL, Berger MS. The surgical management of diffuse gliomas: current state of neurosurgical management and future directions. Neuro Oncol. 2023;25(12):2117\u20132133."},{"issue":"2","key":"b21","series-title":"Curr Neurol Neurosci Rep","first-page":"517","article-title":"The value of extent of resection of glioblastomas: clinical evidence and current approach","volume":"15","author":"Almeida JP","year":"2015","unstructured":"Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep. 2015;15(2):517."},{"issue":"1","key":"b22","series-title":"J Neurosurg","first-page":"3","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai N","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3\u20138."},{"issue":"1","key":"b23","series-title":"J Neurosurg","first-page":"1","article-title":"Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma","volume":"136","author":"Vivas-Buitrago T","year":"2022","unstructured":"Vivas-Buitrago T, Domingo RA, Tripathi S,  Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg. 2022;136(1):1\u20138."},{"issue":"2","key":"b24","series-title":"Neuro Oncol","first-page":"315","article-title":"DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients","volume":"25","author":"Drexler R","year":"2023","unstructured":"Drexler R, Sch\u00fcller U, Eckhardt A,  DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol. 2023;25(2):315\u2013325."},{"issue":"1","key":"b25","series-title":"PLoS One","first-page":"e0169292","article-title":"Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology","volume":"12","author":"Eidel O","year":"2017","unstructured":"Eidel O, Burth S, Neumann JO,  Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One. 2017;12(1):e0169292."},{"issue":"2","key":"b26","series-title":"J Neurosurg","first-page":"190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix M","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR,  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190\u2013198."},{"issue":"3","key":"b27","series-title":"Radiology","first-page":"793","article-title":"Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors","volume":"240","author":"Petrella JR","year":"2006","unstructured":"Petrella JR, Shah LM, Harris KM,  Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. Radiology. 2006;240(3):793\u2013802."},{"issue":"3","key":"b28","series-title":"Neurosurgery","first-page":"564","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer W","year":"2008","unstructured":"Stummer W, Reulen HJ, Meinel T,  Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564\u2013576."},{"issue":"1-2","key":"b29","series-title":"World Neurosurg","first-page":"e257","article-title":"When gross total resection of a glioblastoma is possible, how much resection should be achieved?","volume":"82","author":"Chaichana KL","year":"2014","unstructured":"Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I,  When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg. 2014;82(1-2):e257\u2013e265."},{"issue":"5","key":"b30","series-title":"J Neurosurg","first-page":"1115","article-title":"Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma","volume":"121","author":"Grabowski MM","year":"2014","unstructured":"Grabowski MM, Recinos PF, Nowacki AS,  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115\u20131123."},{"issue":"5","key":"b31","series-title":"J Neurosurg","first-page":"851","article-title":"Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival","volume":"117","author":"Orringer D","year":"2012","unstructured":"Orringer D, Lau D, Khatri S,  Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851\u2013859."},{"key":"b32","series-title":"World Neurosurg","first-page":"e147","article-title":"Correlation between the residual tumor volume, extent of tumor resection, and O6-methylguanine DNA methyltransferase status in patients with glioblastoma","volume":"116","author":"Sharma M","year":"2018","unstructured":"Sharma M, Bellamkonda S, Mohapatra S,  Correlation between the residual tumor volume, extent of tumor resection, and O6-methylguanine DNA methyltransferase status in patients with glioblastoma. World Neurosurg. 2018;116:e147\u2013e161."},{"issue":"3","key":"b33","series-title":"J Neurooncol","first-page":"537","article-title":"Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?","volume":"153","author":"Mareike M","year":"2021","unstructured":"Mareike M, Franziska S-B, Julia E,  Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. J Neurooncol. 2021;153(3):537\u2013545."},{"issue":"4","key":"b34","series-title":"Pediatr Blood Cancer","first-page":"403","article-title":"MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma","volume":"48","author":"Donson AM","year":"2007","unstructured":"Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48(4):403\u2013407."},{"issue":"9","key":"b35","series-title":"Neuro Oncol","first-page":"1457","article-title":"MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review","volume":"23","author":"Brandner S","year":"2021","unstructured":"Brandner S, McAleenan A, Kelly C,  MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol. 2021;23(9):1457\u20131469."},{"issue":"10","key":"b36","series-title":"JAMA Oncol","first-page":"1405","article-title":"Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology\/RTOG 0424 trial","volume":"4","author":"Bell EH","year":"2018","unstructured":"Bell EH, Zhang P, Fisher BJ,  Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology\/RTOG 0424 trial. JAMA Oncol. 2018;4(10):1405\u20131409."},{"issue":"4","key":"b37","series-title":"JAMA Oncol","first-page":"495","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro AM","year":"2020","unstructured":"Molinaro AM, Hervey-Jumper S, Morshed RA,  Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495\u2013503."},{"issue":"1","key":"b38","series-title":"Neurooncol Adv","first-page":"vdab171","article-title":"Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study","volume":"3","author":"Poon MTC","year":"2021","unstructured":"Poon MTC, Keni S, Vimalan V,  Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. Neurooncol Adv. 2021;3(1):vdab171."},{"issue":"5","key":"b39","series-title":"Trends Cancer","first-page":"380","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler M","year":"2020","unstructured":"Butler M, Pongor L, Su YT,  MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380\u2013391."},{"issue":"4","key":"b40","series-title":"J Pers Med","first-page":"290","article-title":"Deep learning can differentiate IDH-mutant from IDH-wild GBM","volume":"11","author":"Pasquini L","year":"2021","unstructured":"Pasquini L, Napolitano A, Tagliente E,  Deep learning can differentiate IDH-mutant from IDH-wild GBM. J Pers Med. 2021;11(4):290."},{"key":"b41","series-title":"World Neurosurg","first-page":"e46","article-title":"Supratotal resection: an emerging concept of glioblastoma multiforme surgery-systematic review and meta-analysis","volume":"179","author":"Aziz PA","year":"2023","unstructured":"Aziz PA, Memon SF, Hussain M,  Supratotal resection: an emerging concept of glioblastoma multiforme surgery-systematic review and meta-analysis. World Neurosurg. 2023;179:e46\u2013e55."},{"issue":"11","key":"b42","series-title":"N Engl J Med","first-page":"1027","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry JR","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ,  Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027\u20131037."},{"issue":"6","key":"b43","series-title":"Neurosurg Focus","first-page":"E16","article-title":"Disparities in health care determine prognosis in newly diagnosed glioblastoma","volume":"44","author":"Chandra A","year":"2018","unstructured":"Chandra A, Rick JW, Dalle Ore C,  Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus. 2018;44(6):E16."},{"issue":"4","key":"b44","series-title":"BMJ Open","first-page":"e082274","article-title":"SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201)","volume":"14","author":"Gerritsen JKW","year":"2024","unstructured":"Gerritsen JKW, Young JS, Chang SM,  SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201). BMJ Open. 2024;14(4):e082274."},{"issue":"9","key":"b45","series-title":"BMJ Open","first-page":"e081689","article-title":"Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202)","volume":"14","author":"Gerritsen JKW","year":"2024","unstructured":"Gerritsen JKW, Young JS, Krieg SM,  Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202). BMJ Open. 2024;14(9):e081689."},{"issue":"1","key":"b46","series-title":"Sci Rep","first-page":"11398","article-title":"Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management","volume":"14","author":"Rosas-Alonso R","year":"2024","unstructured":"Rosas-Alonso R, Colmenarejo-Fern\u00e1ndez J, Pern\u00eda O,  Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management. Sci Rep. 2024;14(1):11398."},{"issue":"1","key":"b47","series-title":"Sci Rep","first-page":"16031","article-title":"Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis","volume":"14","author":"Li L","year":"2024","unstructured":"Li L, Xiao F, Wang S,  Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis. Sci Rep. 2024;14(1):16031."},{"issue":"1","key":"b48","series-title":"Neurooncol Adv","first-page":"vdab149","article-title":"Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy","volume":"3","author":"Djirackor L","year":"2021","unstructured":"Djirackor L, Halldorsson S, Niehusmann P,  Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy. Neurooncol Adv. 2021;3(1):vdab149."},{"issue":"2","key":"b49","series-title":"Clinical article. J Neurosurg","first-page":"220","article-title":"Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution","volume":"115","author":"Marina O","year":"2011","unstructured":"Marina O, Suh JH, Reddy CA,  Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg. 2011;115(2):220\u2013229."},{"issue":"Supplement_6","key":"b1","series-title":"Neuro Oncol","first-page":"vi1","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021","volume":"26","author":"Price M","year":"2024","unstructured":"Price M, Ballard C, Benedetti J,  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021. Neuro Oncol. 2024;26(Supplement_6):vi1-vi85."},{"issue":"23","key":"b2","series-title":"JAMA","first-page":"2535","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp R","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA,  Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535\u20132543."},{"issue":"1","key":"b3","series-title":"Neurosurgery","first-page":"190","article-title":"Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas","volume":"84","author":"Gessler F","year":"2019","unstructured":"Gessler F, Bernstock JD, Braczynski A,  Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas. Neurosurgery. 2019;84(1):190\u2013197."},{"issue":"2","key":"b4","series-title":"Neuro Oncol","first-page":"116","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera AL","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR,  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12(2):116\u2013121."},{"key":"b5","series-title":"Front Oncol","first-page":"1569","article-title":"The impact of surgery in IDH 1 wild type glioblastoma in relation with the MGMT deregulation","volume":"9","author":"Marchi F","year":"2019","unstructured":"Marchi F, Sahnane N, Cerutti R,  The impact of surgery in IDH 1 wild type glioblastoma in relation with the MGMT deregulation. Front Oncol. 2019;9:1569."},{"issue":"5","key":"b6","series-title":"Neuro Oncol","first-page":"940","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia P","year":"2023","unstructured":"Karschnia P, Young JS, Dono A,  Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol. 2023;25(5):940\u2013954."},{"issue":"11","key":"b7","series-title":"JAMA Oncol","first-page":"1460","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown TJ","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M,  Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460\u20131469."},{"issue":"12","key":"b8","series-title":"Ann Oncol","first-page":"3117","article-title":"Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy","volume":"24","author":"Kreth FW","year":"2013","unstructured":"Kreth FW, Thon N, Simon M,  Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117\u20133123."},{"issue":"1","key":"b9","series-title":"J Neurosurg","first-page":"156","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt MJ","year":"2009","unstructured":"McGirt MJ, Chaichana KL, Gathinji M,  Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156\u2013162."},{"issue":"1","key":"b10","series-title":"J Neurooncol","first-page":"207","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy M","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA,  Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207\u2013212."},{"issue":"10","key":"b11","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ,  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u2013996."},{"issue":"6","key":"b12","series-title":"J Pers Med","first-page":"999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan K","year":"2023","unstructured":"Ashkan K, Baig Mirza A, Soumpasis C,  MGMT promoter methylation: prognostication beyond treatment response. J Pers Med. 2023;13(6):999."},{"issue":"4","key":"b13","series-title":"Neurosurgery","first-page":"E323","article-title":"MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold","volume":"88","author":"Katsigiannis S","year":"2021","unstructured":"Katsigiannis S, Grau S, Krischek B,  MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold. Neurosurgery. 2021;88(4):E323\u2013E329."},{"key":"b14","series-title":"Front Oncol","first-page":"1087","article-title":"The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma","volume":"10","author":"Incekara F","year":"2020","unstructured":"Incekara F, Smits M, van der Voort SR,  The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma. Front Oncol. 2020;10:1087."},{"issue":"5","key":"b15","series-title":"Neuro Oncol","first-page":"958","article-title":"Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups","volume":"25","author":"Gerritsen JKW","year":"2023","unstructured":"Gerritsen JKW, Zwarthoed RH, Kilgallon JL,  Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups. Neuro Oncol. 2023;25(5):958\u2013972."},{"issue":"12","key":"b16","series-title":"JAMA Oncol","first-page":"1722","article-title":"Using the National Cancer Database for outcomes research: a review","volume":"3","author":"Boffa DJ","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K,  Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722\u20131728."},{"key":"b17","series-title":"ACS","article-title":"Participant user files","unstructured":"Participant user files. ACS. Accessed March 3, 2025. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/puf\/"},{"key":"b18","article-title":"Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition. Vol 6.","year":"2021","unstructured":"Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition. Vol 6. International Agency for Research on Cancer (IARC);2021. Accessed June 10, 2025. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Central-Nervous-System-Tumours-2021"},{"issue":"5","key":"b19","series-title":"J Chronic Dis","first-page":"373","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u2013383."},{"issue":"12","key":"b20","series-title":"Neuro Oncol","first-page":"2117","article-title":"The surgical management of diffuse gliomas: current state of neurosurgical management and future directions","volume":"25","author":"Young JS","year":"2023","unstructured":"Young JS, Morshed RA, Hervey-Jumper SL, Berger MS. The surgical management of diffuse gliomas: current state of neurosurgical management and future directions. Neuro Oncol. 2023;25(12):2117\u20132133."},{"issue":"2","key":"b21","series-title":"Curr Neurol Neurosci Rep","first-page":"517","article-title":"The value of extent of resection of glioblastomas: clinical evidence and current approach","volume":"15","author":"Almeida JP","year":"2015","unstructured":"Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep. 2015;15(2):517."},{"issue":"1","key":"b22","series-title":"J Neurosurg","first-page":"3","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai N","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3\u20138."},{"issue":"1","key":"b23","series-title":"J Neurosurg","first-page":"1","article-title":"Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma","volume":"136","author":"Vivas-Buitrago T","year":"2022","unstructured":"Vivas-Buitrago T, Domingo RA, Tripathi S,  Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg. 2022;136(1):1\u20138."},{"issue":"2","key":"b24","series-title":"Neuro Oncol","first-page":"315","article-title":"DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients","volume":"25","author":"Drexler R","year":"2023","unstructured":"Drexler R, Sch\u00fcller U, Eckhardt A,  DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol. 2023;25(2):315\u2013325."},{"issue":"1","key":"b25","series-title":"PLoS One","first-page":"e0169292","article-title":"Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology","volume":"12","author":"Eidel O","year":"2017","unstructured":"Eidel O, Burth S, Neumann JO,  Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One. 2017;12(1):e0169292."},{"issue":"2","key":"b26","series-title":"J Neurosurg","first-page":"190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix M","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR,  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190\u2013198."},{"issue":"3","key":"b27","series-title":"Radiology","first-page":"793","article-title":"Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors","volume":"240","author":"Petrella JR","year":"2006","unstructured":"Petrella JR, Shah LM, Harris KM,  Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. Radiology. 2006;240(3):793\u2013802."},{"issue":"3","key":"b28","series-title":"Neurosurgery","first-page":"564","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer W","year":"2008","unstructured":"Stummer W, Reulen HJ, Meinel T,  Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564\u2013576."},{"issue":"1-2","key":"b29","series-title":"World Neurosurg","first-page":"e257","article-title":"When gross total resection of a glioblastoma is possible, how much resection should be achieved?","volume":"82","author":"Chaichana KL","year":"2014","unstructured":"Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I,  When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg. 2014;82(1-2):e257\u2013e265."},{"issue":"5","key":"b30","series-title":"J Neurosurg","first-page":"1115","article-title":"Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma","volume":"121","author":"Grabowski MM","year":"2014","unstructured":"Grabowski MM, Recinos PF, Nowacki AS,  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115\u20131123."},{"issue":"5","key":"b31","series-title":"J Neurosurg","first-page":"851","article-title":"Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival","volume":"117","author":"Orringer D","year":"2012","unstructured":"Orringer D, Lau D, Khatri S,  Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851\u2013859."},{"key":"b32","series-title":"World Neurosurg","first-page":"e147","article-title":"Correlation between the residual tumor volume, extent of tumor resection, and O6-methylguanine DNA methyltransferase status in patients with glioblastoma","volume":"116","author":"Sharma M","year":"2018","unstructured":"Sharma M, Bellamkonda S, Mohapatra S,  Correlation between the residual tumor volume, extent of tumor resection, and O6-methylguanine DNA methyltransferase status in patients with glioblastoma. World Neurosurg. 2018;116:e147\u2013e161."},{"issue":"3","key":"b33","series-title":"J Neurooncol","first-page":"537","article-title":"Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?","volume":"153","author":"Mareike M","year":"2021","unstructured":"Mareike M, Franziska S-B, Julia E,  Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. J Neurooncol. 2021;153(3):537\u2013545."},{"issue":"4","key":"b34","series-title":"Pediatr Blood Cancer","first-page":"403","article-title":"MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma","volume":"48","author":"Donson AM","year":"2007","unstructured":"Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48(4):403\u2013407."},{"issue":"9","key":"b35","series-title":"Neuro Oncol","first-page":"1457","article-title":"MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review","volume":"23","author":"Brandner S","year":"2021","unstructured":"Brandner S, McAleenan A, Kelly C,  MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol. 2021;23(9):1457\u20131469."},{"issue":"10","key":"b36","series-title":"JAMA Oncol","first-page":"1405","article-title":"Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology\/RTOG 0424 trial","volume":"4","author":"Bell EH","year":"2018","unstructured":"Bell EH, Zhang P, Fisher BJ,  Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology\/RTOG 0424 trial. JAMA Oncol. 2018;4(10):1405\u20131409."},{"issue":"4","key":"b37","series-title":"JAMA Oncol","first-page":"495","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro AM","year":"2020","unstructured":"Molinaro AM, Hervey-Jumper S, Morshed RA,  Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495\u2013503."},{"issue":"1","key":"b38","series-title":"Neurooncol Adv","first-page":"vdab171","article-title":"Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study","volume":"3","author":"Poon MTC","year":"2021","unstructured":"Poon MTC, Keni S, Vimalan V,  Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. Neurooncol Adv. 2021;3(1):vdab171."},{"issue":"5","key":"b39","series-title":"Trends Cancer","first-page":"380","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler M","year":"2020","unstructured":"Butler M, Pongor L, Su YT,  MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380\u2013391."},{"issue":"4","key":"b40","series-title":"J Pers Med","first-page":"290","article-title":"Deep learning can differentiate IDH-mutant from IDH-wild GBM","volume":"11","author":"Pasquini L","year":"2021","unstructured":"Pasquini L, Napolitano A, Tagliente E,  Deep learning can differentiate IDH-mutant from IDH-wild GBM. J Pers Med. 2021;11(4):290."},{"key":"b41","series-title":"World Neurosurg","first-page":"e46","article-title":"Supratotal resection: an emerging concept of glioblastoma multiforme surgery-systematic review and meta-analysis","volume":"179","author":"Aziz PA","year":"2023","unstructured":"Aziz PA, Memon SF, Hussain M,  Supratotal resection: an emerging concept of glioblastoma multiforme surgery-systematic review and meta-analysis. World Neurosurg. 2023;179:e46\u2013e55."},{"issue":"11","key":"b42","series-title":"N Engl J Med","first-page":"1027","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry JR","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ,  Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027\u20131037."},{"issue":"6","key":"b43","series-title":"Neurosurg Focus","first-page":"E16","article-title":"Disparities in health care determine prognosis in newly diagnosed glioblastoma","volume":"44","author":"Chandra A","year":"2018","unstructured":"Chandra A, Rick JW, Dalle Ore C,  Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus. 2018;44(6):E16."},{"issue":"4","key":"b44","series-title":"BMJ Open","first-page":"e082274","article-title":"SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201)","volume":"14","author":"Gerritsen JKW","year":"2024","unstructured":"Gerritsen JKW, Young JS, Chang SM,  SUPRAMAX-study: supramaximal resection versus maximal resection for glioblastoma patients: study protocol for an international multicentre prospective cohort study (ENCRAM 2201). BMJ Open. 2024;14(4):e082274."},{"issue":"9","key":"b45","series-title":"BMJ Open","first-page":"e081689","article-title":"Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202)","volume":"14","author":"Gerritsen JKW","year":"2024","unstructured":"Gerritsen JKW, Young JS, Krieg SM,  Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202). BMJ Open. 2024;14(9):e081689."},{"issue":"1","key":"b46","series-title":"Sci Rep","first-page":"11398","article-title":"Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management","volume":"14","author":"Rosas-Alonso R","year":"2024","unstructured":"Rosas-Alonso R, Colmenarejo-Fern\u00e1ndez J, Pern\u00eda O,  Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management. Sci Rep. 2024;14(1):11398."},{"issue":"1","key":"b47","series-title":"Sci Rep","first-page":"16031","article-title":"Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis","volume":"14","author":"Li L","year":"2024","unstructured":"Li L, Xiao F, Wang S,  Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis. Sci Rep. 2024;14(1):16031."},{"issue":"1","key":"b48","series-title":"Neurooncol Adv","first-page":"vdab149","article-title":"Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy","volume":"3","author":"Djirackor L","year":"2021","unstructured":"Djirackor L, Halldorsson S, Niehusmann P,  Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy. Neurooncol Adv. 2021;3(1):vdab149."},{"issue":"2","key":"b49","series-title":"Clinical article. J Neurosurg","first-page":"220","article-title":"Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution","volume":"115","author":"Marina O","year":"2011","unstructured":"Marina O, Suh JH, Reddy CA,  Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg. 2011;115(2):220\u2013229."}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/59\/2\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/59\/2\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/59\/2\/article-pE9.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:15:44Z","timestamp":1780128944000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/59\/2\/article-pE9.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":98,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2025.5.focus25350","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}